ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
129.210,48
0,58%
S&P 500
5.187,70
0,13%
US Dollar vs BRL
5,0752
-0,02%
Bitcoin
63.054,10
-0,18%
Brent Oil
82,865
-0,73%
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Opiant Pharmaceuticals Inc (OPNT)

  7. Opiant Pharmaceuticals Inc (OPNT) Notícias

OPNT

Opiant Pharmaceuticals (OPNT)

Opiant Pharmaceuticals Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:OPNT
DataHoraFonteTítuloCódigoCompanhia
13/03/202307:16Edgar (US Regulatory)Termination of Registration of a Class of Security Under Section 12(g) (15-12g)NASDAQ:OPNTOpiant Pharmaceuticals Inc
10/03/202308:05Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:OPNTOpiant Pharmaceuticals Inc
06/03/202316:02Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NASDAQ:OPNTOpiant Pharmaceuticals Inc
06/03/202315:17Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:OPNTOpiant Pharmaceuticals Inc
03/03/202311:27Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:OPNTOpiant Pharmaceuticals Inc
27/02/202318:05Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:OPNTOpiant Pharmaceuticals Inc
16/02/202319:14Edgar (US Regulatory)Additional Proxy Soliciting Materials - Non-management (definitive) (dfan14a)NASDAQ:OPNTOpiant Pharmaceuticals Inc
07/02/202318:01GlobeNewswire Inc.Opiant Pharmaceuticals Announces CFIUS Approval for Proposed Acquisition by Indivior PLCNASDAQ:OPNTOpiant Pharmaceuticals Inc
06/02/202310:00GlobeNewswire Inc.Opiant Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition by Indivior PLCNASDAQ:OPNTOpiant Pharmaceuticals Inc
19/01/202318:05GlobeNewswire Inc.Opiant Pharmaceuticals Announces FDA Acceptance and Priority Review of NDA for OPNT003, Nasal Nalmefene, for Opioid OverdoseNASDAQ:OPNTOpiant Pharmaceuticals Inc
04/01/202318:21Edgar (US Regulatory)Proxy Statement - Merger or Acquisition (definitive) (defm14a)NASDAQ:OPNTOpiant Pharmaceuticals Inc
21/12/202218:56Edgar (US Regulatory)Proxy Statement - Merger or Acquisition (preliminary) (prem14a)NASDAQ:OPNTOpiant Pharmaceuticals Inc
22/11/202218:01GlobeNewswire Inc.Opiant Pharmaceuticals Announces Completion of Rolling NDA Submission for OPNT003, Nasal Nalmefene, for Opioid OverdoseNASDAQ:OPNTOpiant Pharmaceuticals Inc
15/11/202208:10Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:OPNTOpiant Pharmaceuticals Inc
14/11/202218:25Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:OPNTOpiant Pharmaceuticals Inc
14/11/202206:26TipRanksHow Will Indivior’s $145M Purchase of Opiant Boost the Stock?NASDAQ:OPNTOpiant Pharmaceuticals Inc
14/11/202204:13GlobeNewswire Inc.Opiant Pharmaceuticals Announces Third Quarter 2022 Financial ResultsNASDAQ:OPNTOpiant Pharmaceuticals Inc
14/11/202204:12GlobeNewswire Inc.Indivior PLC to Acquire Opiant PharmaceuticalsNASDAQ:OPNTOpiant Pharmaceuticals Inc
14/11/202204:10PR Newswire (US)Indivior To Acquire Opiant PharmaceuticalsNASDAQ:OPNTOpiant Pharmaceuticals Inc
27/10/202217:05GlobeNewswire Inc.Opiant Pharmaceuticals to Report Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 14, 2022NASDAQ:OPNTOpiant Pharmaceuticals Inc
06/10/202209:01GlobeNewswire Inc.Opiant Pharmaceuticals Announces Completion of Enrollment in Phase 2 Clinical Trial of OPNT002, Nasal Naltrexone, in Patients with Alcohol Use DisorderNASDAQ:OPNTOpiant Pharmaceuticals Inc
22/08/202217:05GlobeNewswire Inc.Opiant Pharmaceuticals Announces Notice of Allowance for U.S. Patent with Claims Covering OPNT004 for the Treatment of Cannabinoid Hyperemesis SyndromeNASDAQ:OPNTOpiant Pharmaceuticals Inc
12/08/202208:30PR Newswire (Canada)MindMed Strengthens Board with Appointment of Two New Independent DirectorsNASDAQ:OPNTOpiant Pharmaceuticals Inc
11/08/202217:05GlobeNewswire Inc.Opiant Pharmaceuticals Announces Second Quarter and First Half 2022 Financial Results and Provides Corporate UpdateNASDAQ:OPNTOpiant Pharmaceuticals Inc
08/08/202217:05GlobeNewswire Inc.Opiant Pharmaceuticals Announces Additional $2.1 Million Funding Under BARDA Contract for OPNT003, Nasal NalmefeneNASDAQ:OPNTOpiant Pharmaceuticals Inc
02/08/202217:05GlobeNewswire Inc.Opiant Pharmaceuticals Announces Notice of Allowance for U.S. Patent With Claims Covering OPNT003 for the Treatment of Opioid OverdoseNASDAQ:OPNTOpiant Pharmaceuticals Inc
01/08/202217:05GlobeNewswire Inc.Opiant Pharmaceuticals to Report Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 11, 2022NASDAQ:OPNTOpiant Pharmaceuticals Inc
28/06/202217:05GlobeNewswire Inc.Opiant Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:OPNTOpiant Pharmaceuticals Inc
17/06/202217:54Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:OPNTOpiant Pharmaceuticals Inc
08/06/202217:05GlobeNewswire Inc.Opiant Pharmaceuticals and Aptar Pharma Expand Long-Term Collaboration for the Manufacture of Unidose Nasal Spray for OPNT003, Nasal NalmefeneNASDAQ:OPNTOpiant Pharmaceuticals Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:OPNT

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
NGRD3
Neogrid Participacoes ON
BOV
IFCM3
Infracommerce Caxaas ON
BOV
AZEV4
AZEVEDO PN
BOV
BHIA3
Grupo Casas Bahia ON
BOV
IRBR3
IRB BRASIL ON
BOV
PCAR3
PÃO DE AÇUCAR ON
BOV
PRIO3
PETRORIO ON
BOV
OIBR3
OI ON
BOV
HAGA3
HAGA ON
BOV
TPIS3
TRIUNFO PART ON
BOV
VVEO3
CM Hospitalar ON
BOV
TELB4
TELEBRAS PN
BOV
BRKM5
BRASKEM PNA
BOV
MNPR3
MINUPAR ON
BOV
AGXY3
Agrogalaxy Participacoes ON
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados